Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 23.2% from a year ago
Cash & equivalents stood at $39.98M at the end of Q3 FY2026, down 23.2% from a year earlier and down 39.1% from the prior quarter. Over 3 fiscal years it compounded at -24.8% a year.
Context
- Cash & equivalents amounted to 9.0% of total assets at the end of Q3 FY2026, down 1.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 54.3M USD
- Year-over-year change
- -39.1%
- 4-year CAGR
- -2.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.3M | -39.1% |
| FY2024 | 2024-12-31 | 89.14M | +48.4% |
| FY2023 | 2023-12-31 | 60.08M | -52.9% |
| FY2022 | 2022-12-31 | 127.68M | +115.5% |
| FY2021 | 2021-12-31 | 59.25M | — |
Cash & Equivalents vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's Sep 2026 cash & equivalents of $39.98M is the 9th highest of the 11 companies compared; the peer median is $164.41M.
- Its year-over-year change of -23.2% is the 7th highest of 10, against a peer median of +24.6%.
- Cash & equivalents amounts to 9.0% of total assets for RYTM, versus a peer median of 29.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $736.01B | +58775.5% | +21.9% | 6.4% | |
| Jun 2026 | $272.64M | +85.4% | +212.9% | 19.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M | -6.1% | +89.8% | 60.8% |
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M | -47.8% | +58.0% | 27.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M | -27.5% | +46.0% | 32.3% |
| Jun 2026 | $125.75M | +271.2% | +65.4% | 24.1% | |
| Mar 2026 | $44.69M | +24.6% | -20.7% | 96.4% | |
| Sep 2026 | $39.98M | -23.2% | -24.8% | 9.0% | |
| Mar 2026 | $10.16M | +303.1% | -55.9% | 76.8% | |
BLTEBelite Bio, Inc | Jun 2026 | $0 | — | +103.2% | 0.0% |
| Peer median (excluding RYTM) | $164.41M | +24.6% | +52.0% | 29.6% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.25M | 127.68M | 60.08M | 89.14M | 54.3M |
| Short-term Investments | 235.61M | 205.61M | 215.77M | 231.43M | 334.65M |
| Net Receivables | 1.03M | 6.22M | 14.87M | 18.51M | 26.08M |
| Inventory | 111K | 2.92M | 8.62M | 18.74M | 25.75M |
| Other Current Assets | 3.99M | 7.42M | 6.67M | 8.8M | 9.97M |
| Total Current Assets | 308.39M | 354.24M | 308.27M | 374.2M | 466.92M |
| Property, Plant & Equipment (Net) | 4.34M | 3.38M | 2.12M | 4.11M | 4.15M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.66M | 7.88M | 7.03M | 6.17M | 5.32M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.14M | 16.98M | 15.33M | 7.79M | 3.81M |
| Total Non-current Assets | 21.14M | 28.25M | 24.48M | 18.07M | 13.28M |
| Total Assets | 329.52M | 382.48M | 332.75M | 392.27M | 480.2M |
| Account Payables | 5.74M | 4.8M | 4.89M | 12.33M | 13.95M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7M | 1.43M | 1.29M | 1.29M | 194K |
| Other Current Liabilities | 800K | 2.42M | 5.41M | 43.6M | 11.37M |
| Total Current Liabilities | 43.43M | 39.81M | 55.2M | 115.52M | 105.94M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 77.15M | 107.29M | 108.27M | 100.89M |
| Total Non-current Liabilities | 1.95M | 78.41M | 107.78M | 112.21M | 104.23M |
| Total Liabilities | 45.37M | 118.22M | 162.99M | 227.72M | 210.17M |
| Common Stock | 50K | 56K | 59K | 61K | 67K |
| Retained Earnings | (528.94M) | (710.06M) | (894.74M) | (1.16B) | (1.35B) |
| Accumulated OCI | (1K) | (92K) | 134K | (39K) | (796K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 284.15M | 264.26M | 169.76M | 164.55M | 270.03M |
| Total Debt | 2.55M | 1.94M | 1.26M | 3.94M | 3.99M |
| Net Debt | (56.7M) | (125.73M) | (58.82M) | (85.2M) | (50.31M) |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.